SYRE
Spyre Therapeutics, Inc. Health Care Pharmaceutical Preparations Russell 3000
$96.56Close
$7.6BMarket cap
$22.18 – $108.9252-week range
Nov 3, 2026Next report
Highlights
Strengths
- In a stage-2 uptrend all 8 trend conditions pass
- Leading the market RS 99 · stronger than 99% of stocks over 12 months
- Volume drying up last 10 days 32% under the 50-day average
Cautions
- Results soon Nov 3, 2026, in 2 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
11%
1wk
up 6.9%
price change
1mo
up 8.5%
price change
12-month return
up 298%
market up 11% ·
its own up 294%
F-score
—
— Not assessed
Altman Z
70.62
Low risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
10.6×
price / book
Earnings yield
down 2.8%
EBIT / enterprise value
Cheaper than
16%
of the market · expensive
Revenue growth
—
year on year
EPS growth
—
latest quarter
Sales growth
—
latest quarter
ROE
down 25%
return on equity
Free cash margin
—
-$169.3M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Trade setup
ATR%
4.8%
$4.63 a day · 2×ATR $87.30
RS
99 / 99
vs the universe
Trend
8 / 8
trend template
Relative volume
0.5×
vs 50-day average
Up/down volume
0.94
50 sessions
Implied move
—
no option chain · report Nov 3, 2026
Trend template · 8 of 8
Screen verdict
Did not qualify for any screen.
Warning signs
- Shareholders diluted The share count rose 29.8% over the year, from 60m to 78m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported
Aug 4, 2026
Last shock
Oct 6, 2026-14% in one session3.5× volumeon an SEC filing+21% since
Financials
- Net
- Free cash
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $18.7M | $2.3M | $886,000 | $0 | $0 |
| Operating income | -$81.5M | -$65.6M | -$84.8M | -$242.3M | -$208.6M | -$209.6M |
| Net income | -$80.9M | -$65.8M | -$83.8M | -$338.8M | -$208.0M | -$155.2M |
| Net margin | — | -351% | -3599% | -38238% | — | — |
| Earnings per share | -$1.52 | -$25.02 | -$24.86 | -$49.12 | — | — |
| Free cash flow | -$80.1M | -$54.3M | -$80.2M | -$99.9M | -$157.4M | -$169.3M |
| Free cash margin | — | -290% | -3443% | -11277% | — | — |
| Cash | $90.1M | $15.1M | $34.9M | $188.9M | $89.4M | $85.7M |
| Shareholders' equity | $139.8M | $83.9M | $50.3M | $184.0M | $517.8M | $715.2M |
| Shares outstanding | 47.96m | 49.36m | 2.61m | 36.06m | 60.26m | 78.19m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 4, 2026 | Quarterly ↗ | Jun 30, 2026 | 35d |
| May 5, 2026 | Quarterly ↗ | Mar 31, 2026 | 35d |
| Feb 19, 2026 | Annual ↗ | Dec 31, 2025 | 50d |
| Nov 4, 2025 | Quarterly ↗ | Sep 30, 2025 | 35d |
| Aug 5, 2025 | Quarterly ↗ | Jun 30, 2025 | 36d |
| May 8, 2025 | Quarterly ↗ | Mar 31, 2025 | 38d |
| Feb 27, 2025 | Annual ↗ | Dec 31, 2024 | 58d |
| Nov 7, 2024 | Quarterly ↗ | Sep 30, 2024 | 38d |
| Aug 7, 2024 | Quarterly ↗ | Jun 30, 2024 | 38d |
| May 9, 2024 | Quarterly ↗ | Mar 31, 2024 | 39d |
| Feb 29, 2024 | Annual ↗ | Dec 31, 2023 | 60d |
| Nov 9, 2023 | Quarterly ↗ | Sep 30, 2023 | 40d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 7, 2026 | Material agreement ↗ |
| Sep 8, 2026 | Regulation FD · Other events ↗ |
| Aug 25, 2026 | Regulation FD · Other events ↗ |
| Aug 4, 2026 | Results ↗ |
| Jun 15, 2026 | Regulation FD · Other events ↗ |
| Jun 1, 2026 | Other events ↗ |
| May 29, 2026 | Director or officer change · Shareholder vote ↗ |
| May 5, 2026 | Results ↗ |
| Apr 16, 2026 | Material agreement ↗ |
| Apr 13, 2026 | Results · Other events ↗ |
| Apr 13, 2026 | Regulation FD · Other events ↗ |
| Feb 19, 2026 | Results ↗ |